|
1
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Furnari FB, Fenton T, Bachoo RM, Mukasa A,
Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al:
Malignant astrocytic glioma: Genetics, biology, and paths to
treatment. Genes Dev. 21:2683–2710. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Scott CB, Scarantino C, Urtasun R, Movsas
B, Jones CU, Simpson JR, Fischbach AJ and Curran WJ Jr: Validation
and predictive power of radiation therapy oncology group (RTOG)
recursive partitioning analysis classes for malignant glioma
patients: A report using RTOG 90-06. Int J Radiat Oncol Biol Phys.
40:51–55. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Visser O, Ardanaz E, Botta L, Sant M,
Tavilla A and Minicozzi P; EUROCARE-5 Working Group, : Survival of
adults with primary malignant brain tumours in Europe; results of
the EUROCARE-5 study. Eur J Cancer. 51:2231–2241. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alifieris C and Trafalis DT: Glioblastoma
multiforme: Pathogenesis and treatment. Pharmacol Ther. 152:63–82.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Alisi A, Cho WC, Locatelli F and Fruci D:
Multidrug resistance and cancer stem cells in neuroblastoma and
hepatoblastoma. Int J Mol Sci. 14:24706–24725. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen J, Li Y, Yu TS, McKay RM, Burns DK,
Kernie SG and Parada LF: A restricted cell population propagates
glioblastoma growth after chemotherapy. Nature. 488:522–526. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Genadry KC, Pietrobono S, Rota R and
Linardic CM: Soft tissue sarcoma cancer stem cells: An overview.
Front Oncol. 8:4752018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Codony-Servat J, Verlicchi A and Rosell R:
Cancer stem cells in small cell lung cancer. Transl Lung Cancer
Res. 5:16–25. 2016.PubMed/NCBI
|
|
12
|
Johnsen HE, Bøgsted M, Schmitz A, Bødker
JS, El-Galaly TC, Johansen P, Valent P, Zojer N, Van Valckenborgh
E, Vanderkerken K, et al: The myeloma stem cell concept, revisited:
From phenomenology to operational terms. Haematologica.
101:1451–1459. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Parte SC, Batra SK and Kakar SS:
Characterization of stem cell and cancer stem cell populations in
ovary and ovarian tumors. J Ovarian Res. 11:692018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Calabrese C, Poppleton H, Kocak M, Hogg
TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, et
al: A perivascular niche for brain tumor stem cells. Cancer Cell.
11:69–82. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Koren E and Fuchs Y: The bad seed: Cancer
stem cells in tumor development and resistance. Drug Resist Updat.
28:1–12. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lathia JD, Mack SC, Mulkearns-Hubert EE,
Valentim CL and Rich JN: Cancer stem cells in glioblastoma. Genes
Dev. 29:1203–1217. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ignatova TN, Kukekov VG, Laywell ED,
Suslov ON, Vrionis FD and Steindler DA: Human cortical glial tumors
contain neural stem-like cells expressing astroglial and neuronal
markers in vitro. Glia. 39:193–206. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bexell D, Svensson A and Bengzon J: Stem
cell-based therapy for malignant glioma. Cancer Treat Rev.
39:358–365. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bovenberg MS, Degeling MH and Tannous BA:
Advances in stem cell therapy against gliomas. Trends Mol Med.
19:281–291. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang T, Shigdar S, Gantier MP, Hou Y, Wang
L, Li Y, Shamaileh HA, Yin W, Zhou SF, Zhao X and Duan W: Cancer
stem cell targeted therapy: Progress amid controversies.
Oncotarget. 6:44191–44206. 2015.PubMed/NCBI
|
|
21
|
Colak S and Medema JP: Cancer stem
cells-important players in tumor therapy resistance. FEBS J.
281:4779–4791. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lage H: An overview of cancer multidrug
resistance: A still unsolved problem. Cell Mol Life Sci.
65:3145–3167. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Folkins C, Shaked Y, Man S, Tang T, Lee
CR, Zhu Z, Hoffman RM and Kerbel RS: Glioma tumor stem-like cells
promote tumor angiogenesis and vasculogenesis via vascular
endothelial growth factor and stromal-derived factor 1. Cancer Res.
69:7243–7251. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bao S, Wu Q, Sathornsumetee S, Hao Y, Li
Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD and Rich JN: Stem
cell-like glioma cells promote tumor angiogenesis through vascular
endothelial growth factor. Cancer Res. 66:7843–7848. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pietras A, Gisselsson D, Ora I, Noguera R,
Beckman S, Navarro S and Påhlman S: High levels of HIF-2alpha
highlight an immature neural crest-like neuroblastoma cell cohort
located in a perivascular niche. J Pathol. 214:482–488. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li Z, Bao S, Wu Q, Wang H, Eyler C,
Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, et al:
Hypoxia-inducible factors regulate tumorigenic capacity of glioma
stem cells. Cancer Cell. 15:501–513. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Plate KH and Risau W: Angiogenesis in
malignant gliomas. Glia. 15:339–347. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mondal S, Bandyopadhyay S, Ghosh MK,
Mukhopadhyay S, Roy S and Mandal C: Natural products: Promising
resources for cancer drug discovery. Anticancer Agents Med Chem.
12:49–75. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Moselhy J, Srinivasan S, Ankem MK and
Damodaran C: Natural products that target cancer stem cells.
Anticancer Res. 35:5773–5788. 2015.PubMed/NCBI
|
|
30
|
Thies PW and Funke S: On the active
ingredients in baldrian. 1. Detection and isolation of isovalerian
acid esters with sedative effect from roots and rhizomes of various
valerian and kentranthus species. Tetrahedron Lett. 11:1155–1162.
1966.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thies PW: Linarin-isovalerianate, a
currently unknown flavonoid from Valeriana wallichii D.C. 6. Report
on the active substances of Valeriana. Planta Med. 16:363–371.
1968.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Thies PW: Valerosidatum, ein
iridoidesterglycosid aus valeriana-arten 7. mitteilung über die
wirkstoffe des baldrians. Tetrahedron Lett. 11:2471–2474. 1970.
View Article : Google Scholar
|
|
33
|
Yang XP, Li EW, Zhang Q, Yuan CS and Jia
ZJ: Five new iridoids from Patrinia rupestris. Chem Biodivers.
3:762–770. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dong FW, Jiang HH, Yang L, Gong Y, Zi CT,
Yang D, Ye CJ, Li H, Yang J, Nian Y, et al: Valepotriates from the
roots and rhizomes of Valeriana jatamansi jones as Novel
N-type calcium channel antagonists. Front Pharmacol. 9:8852018.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dong FW, Liu Yang, Wu ZK, Wei-Gao, Zi CT,
Dan Yang, Luo HR, Jun Zhou and Hu JM: Iridoids and sesquiterpenoids
from the roots of Valeriana jatamansi jones. Fitoterapia.
102:27–34. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lin S, Chen T, Liu XH, Shen YH, Li HL,
Shan L, Liu RH, Xu XK, Zhang WD and Wang H: Iridoids and lignans
from Valeriana jatamansi. J Nat Prod. 73:632–638. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee J, Kotliarova S, Kotliarov Y, Li A, Su
Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, et al:
Tumor stem cells derived from glioblastomas cultured in bFGF and
EGF more closely mirror the phenotype and genotype of primary
tumors than do serum-cultured cell lines. Cancer cell. 9:391–403.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wilson RJ, Thomas CD, Fox R, Roy DB and
Kunin WE: Spatial patterns in species distributions reveal
biodiversity change. Nature. 432:393–396. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dai Z, Li SR, Zhu PF, Liu L, Wang B, Liu
YP, Luo XD and Zhao XD: Isocostunolide inhibited glioma stem cell
by suppression proliferation and inducing caspase dependent
apoptosis. Bioorg Med Chem Lett. 27:2863–2867. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang B, Dai Z, Yang XW, Liu YP, Khan A,
Yang ZF, Huang WY, Wang XH, Zhao XD and Luo XD: Novel
nor-monoterpenoid indole alkaloids inhibiting glioma stem cells
from fruits of Alstonia scholaris. Phytomedicine. 48:170–178. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wei X, Dai Z, Yang J, Khan A, Yu HF, Zhao
YL, Wang YF, Liu YP, Yang ZF, Huang WY, et al: Unprecedented sugar
bridged bisindoles selective inhibiting glioma stem cells. Bioorg
Med Chem. 26:1776–1783. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang XW, Dai Z, Wang B, Liu YP, Zhao XD
and Luo XD: Antitumor triterpenoid saponin from the fruits of
avicennia marina. Nat Prod Bioprospect. 8:347–353. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen J, Creed A, Chen AY, Huang H, Li Z,
Rankin GO, Ye X, Xu G and Chen YC: Nobiletin suppresses cell
viability through AKT pathways in PC-3 and DU-145 prostate cancer
cells. BMC Pharmacol Toxicol. 15:592014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ning H, Albersen M, Lin G, Lue TF and Lin
CS: Effects of EdU labeling on mesenchymal stem cells. Cytotherapy.
15:57–63. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Borowicz S, Van Scoyk M, Avasarala S,
Karuppusamy Rathinam MK, Tauler J, Bikkavilli RK and Winn RA: The
soft agar colony formation assay. J Vis Exp. e519982014.PubMed/NCBI
|
|
46
|
Franken NA, Rodermond HM, Stap J, Haveman
J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc.
1:2315–2319. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bien-Möller S, Balz E, Herzog S, Plantera
L, Vogelgesang S, Weitmann K, Seifert C, Fink MA, Marx S, Bialke A,
et al: Association of glioblastoma multiforme stem cell
characteristics, differentiation, and microglia marker genes with
patient survival. Stem Cells Int. 2018:96282892018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Danovi D, Folarin A, Gogolok S, Ender C,
Elbatsh AM, Engström PG, Stricker SH, Gagrica S, Georgian A, Yu D,
et al: A high-content small molecule screen identifies sensitivity
of glioblastoma stem cells to inhibition of polo-like kinase 1.
PLoS One. 8:e770532013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hothi P, Martins TJ, Chen L, Deleyrolle L,
Yoon JG, Reynolds B and Foltz G: High-throughput chemical screens
identify disulfiram as an inhibitor of human glioblastoma stem
cells. Oncotarget. 3:1124–1136. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Junca A, Villalva C, Tachon G, Rivet P,
Cortes U, Guilloteau K, Balbous A, Godet J, Wager M and
Karayan-Tapon L: Crizotinib targets in glioblastoma stem cells.
Cancer Med. 6:2625–2634. 2017. View Article : Google Scholar : PubMed/NCBI
|
